—A Pharmacor Analyst Call from Decision Resources
Based on our Pharmacor Hepatitis C Virus advisory service, Decision Resources is offering this exclusive analyst call entitled Interferon-Free Therapies for Hepatitis C Virus Take Center Stage - Highlights from AASLD’s 2011 Liver Meeting. Because this analyst call will feature major findings, it is ONLY available to purchasers of this Pharmacor advisory service.
Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call.
After the historic launches earlier this year of the first two HCV-specific protease inhibitors, expectations were high at the American Society for the Study of Liver Disease’s (AASLD) 2011 Liver Meeting where numerous developers presented promising data for HCV-specific Phase II and III antivirals. Among the agents striving to be included in the first interferon-free regimens, Pharmasset’s nucleoside polymerase inhibitor PSI-7977, Bristol-Myers Squibb’s NS5A inhibitor daclatasvir, Boehringer Ingelheim’s protease inhibitor BI-201335 and Novartis/Debiopharm’s alisporivir grabbed the limelight at the conference. Encouraging Phase III trial results for these therapies strengthen the growing recognition that highly effective, safe and convenient interferon-free regimens may be available in the near future. The company that successfully brings the first interferon-free combination to market will be well-positioned to capitalize on the significant population of diagnosed patients who are unable or unwilling to undergo interferon-based treatment.
At the Liver Meeting, trial data were also presented from studies evaluating HCV antivirals in specific patient subpopulations. These include interferon-based studies of Vertex’s Incivek and Merck/Roche’s Victrelis in HIV/HCV co-infected individuals and Medivir/Johnson & Johnson’s second-generation protease inhibitor simeprevir in cirrhotic genotype 1-infected nonresponders.
This 15-minute analyst call, presented by Decision Resources Analyst Seamus Levine-Wilkinson, Ph.D., will answer the following questions:
- What drug development strategies are companies pursuing to position their emerging therapies competitively in a potentially crowded future HCV market?
- What are thought leaders perceptions of the competitive advantages of emerging HCV therapies?
- What steps are the developers taking to solidify the position of recently launched protease inhibitors, Vertex/Johnson & Johnson/Tanabe Pharma’s Incivek and Merck/Roche’s Victrelis?
Dr. Levine-Wilkinson will conduct a live Q & A session after the presentation.
Interferon-Free Therapies for Hepatitis C Virus Take Center Stage - Highlights from AASLD’s 2011 Liver Meeting
December 1, 2011 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).
Webinar Details Date & Time Duration: 15 minutes |
About the Speaker Seamus Levine-Wilkinson, Ph.D., is an analyst in Decision Resources’ infectious disease group. He earned a doctorate in cellular, molecular and developmental biology and biophysics at Johns Hopkins University. In his dissertation, he focused on the host cell biology of Salmonella-induced tubules and incorporated live-cell imaging studies of invasive Salmonella in epithelial cells. |
|
To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America In Europe In Japan |
Terms of Use | Privacy Policy | Contact Us | Careers
Decision Resources • 8 New England Executive Park • Burlington, MA 01803
You are receiving this email because you have previously requested information from Decision Resources. You can update your email preferences at any time.
© 2011 Decision Resources, LLC. All rights reserved.
